Enter inventor name

Andre J Monteil

This inventor holds 18 USPTO granted patents. Top assignees: Centre Europeen De Recherches Mauvernay, Akzo N.v., Centre Europeen De Recherches Mauvernay 'Cerm'. Active years: 1976-1993.

USPTO Granted Patents = 18

% Patents Active = 100.0

Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 77(Granted Patents)

Location History:

63400 Chamalieres, FR (1976)
Gerzat, FR (1976 - 1978)
Chatel-Guyon, FR (1977 - 1993)

Company Filing History:

4 out of 6

Centre Europeen De Recherches Mauvernay

Centre Europeen De Recherches Mauvernay 'Cerm'

patents

4. 3 out of 3

Riom Laboratoires C.e.r.m. 'Rl-Cerm' S.a.

patents

5. 1 out of 1

Centre European De Recherches Mauvernay

patent

6. 1 out of 1

Riom Laboratoires C.e.r.m.

patent

7. 1 out of 3

Riom Laboratories C.e.r.m.

patents

8. 1 out of 1

Societe Anonyme Dite: Centre Europen De Recherches Mauvernay (c.e.r.m.)

patent

9. 1 out of 834,411

Other

patents

Years Active: 1976-1993

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 5180726 - 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinylalkyl substituted (1993-01-19),

2. 5135931 - Pyridinylpiperazine derivatives (1992-08-04),

3. 4971969 - Pharmaceutical composition containing 1-(mono- or (1990-11-20),

4. 4822792 - Substituted 3-piperidinamines or 3-azepinamines, the preparation thereof (1989-04-18),

5. 4820702 - New substituted piperidine or azepine compounds which have useful (1989-04-11),

6. 4762834 - 3-alkoxy-2-(N-pyrrolidino)-N-pyrimidinyl- or -N-pyrazinolpropylamines (1988-08-09),

7. 4645778 - 2-(N-pyrrolidino)-3-isobutoxy-n-substituted-phenyl-n-benzyl-propylamines, (1987-02-24),

8. 4555514 - 3-Alkoxy-2-(N-pyrolidino)-N-pyridyl-N-furyl(or thienyl) methyl-pyropyl (1985-11-26),

9. 4430332 - Ethers of 1-(2-propynyloxy)-2-amino-3-propanol (1984-02-07),

10. 4086352 - Certain 6-aryloxy-2-oxo-1-aza-4-thia-spiro[4,5]decanes (1978-04-25),

11. 4062956 - Substituted 2-(2-hydroxyethyl)tetrahydro-1,4 oxazines and quaternary (1977-12-13),

12. 4035498 - Pharmaceutically active compounds and the preparation thereof (1977-07-12),

13. 4029790 - 1-Benzoyl-2 or 4 [2-(4-phenyl-piperazino)-ethyl]-piperidines (1977-06-14),

14. 4011240 - Substituted cysteines (1977-03-08),

15. 4008329 - Substituted cyclohexanes, pharmaceutical compositions containing them (1977-02-15),

Title: The Innovative Contributions of Andre J Monteil

Introduction

Andre J Monteil is a notable inventor based in Chatel-Guyon, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of neuroleptic and antidepressant compounds. With a total of 18 patents to his name, Monteil's work has had a considerable impact on medicinal chemistry.

Latest Patents

Monteil's latest patents include innovative compounds such as 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinylalkyl substituted lactam derivatives. This invention relates to neuroleptic and antidepressant compounds that exhibit a specific structural formula. Another significant patent involves pyridinylpiperazine derivatives, which display improved preferential serotonin-1A binding activity. These compounds are designed to enhance therapeutic efficacy in treating various mental health conditions.

Career Highlights

Throughout his career, Monteil has worked with esteemed organizations such as the Centre Européen de Recherches Mauvernay. His research has focused on developing novel pharmaceutical agents that address critical health issues. His dedication to innovation in the field has earned him recognition among his peers.

Collaborations

Monteil has collaborated with notable individuals in the industry, including Jacques A Simond and Jacques Moleyre. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Andre J Monteil's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a leading inventor. His work continues to influence the development of new therapeutic agents that can improve patient outcomes.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]